Delivery Order SPE2DP20D0002-SPE2DP25F9616
Award Date 7/14/25
Potential Completion Date 7/29/25
Potential Value $826K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $660,627.72 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents continued federal procurement from Teva as a critical supplier of vaccines and pharmaceutical products to military immunization programs. The contract will be performed at...
- The Department of Defense's Medical Supply Chain awarded a $165,156.93 delivery order to Teva Pharmaceuticals USA, Inc. on December 1, 2025, for the supply of Adenovirus Type 4 vaccine. This firm-fixed-price delivery order, with an ultimate completion date of December 9, 2025, represents part of Teva's extensive portfolio supporting critical military immunization programs. The contract contains no set-aside designation and will be performed at Teva's manufacturing facility in Parsippany, New...
- The Defense Logistics Agency awarded Teva Pharmaceuticals USA, Inc. a firm fixed-price delivery order valued at $165,156.93 for Adenovirus Type 4 vaccine with an ultimate completion date of September 23, 2025. The contract, issued without a set-aside designation, is being performed in Parsippany, New Jersey, where Teva maintains its U.S. headquarters. This delivery order supports the Department of Defense's immunization programs and represents part of Teva's established role as a critical...
- Teva Pharmaceuticals USA, Inc. has been awarded a firm fixed-price delivery order valued at $330,313.86 for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. The contract, issued without set-aside designation by the Defense Logistics Agency Troop Support Medical on December 1, 2025, will be performed at Teva's facility in Parsippany, New Jersey. This delivery order represents one of over 150 similar awards issued to Teva since 2023, positioning the company as a...
- The Department of Defense's Medical Supply Chain issued a delivery order valued at $1.98M to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents one of over 150 similar awards to Teva since 2023 under indefinite delivery contract vehicles managed by the Defense Logistics Agency Troop Support Medical. The Adenovirus Type 4 vaccine...
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a firm-fixed-price delivery order valued at $165,156.93 to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine. The contract was awarded on May 12, 2025, with an ultimate completion date of May 20, 2025, and is being performed at Teva's facility in Parsippany, New Jersey. This delivery order was issued without a set-aside designation, allowing competition among all qualified vendors. The...
- This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. The contract has a ceiling value of $317,609.46 and a period of performance through November 19, 2024. The award is unrestricted, meaning Teva competed as a large business without any set-aside designations. Teva is a major pharmaceutical supplier to federal...
- The U.S. government agency Defense Logistics Agency (DLA) Troop Support Medical awarded a $158,804.73 firm-fixed-price delivery order contract to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. This delivery order is part of a larger contract vehicle, and Teva has received multiple prior delivery orders for this vaccine to support military immunization programs. Teva also holds several significant Indefinite...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a $146,823.93 firm fixed price delivery order to Teva Pharmaceuticals USA, Inc., a pharmaceutical manufacturer, to provide adenovirus type 4 vaccine. This order supports military immunization programs. Teva Pharmaceuticals USA, Inc. is a foreign-owned, for-profit organization that manufactures a range of drug products, including vaccines, antivirals, respiratory treatments, and multiple sclerosis medications for federal customers...